I/We claim:

1. ~~A~~Use of a cannabinoid composition in the manufacture of a medicament for the treatment of a neurodegenerative disease, wherein the cannabinoid composition comprises~~ing~~: cannabidiol and cannabigerol, wherein a mass ratio of the cannabidiol to the cannabigerol is from~~between~~ 1:1 to~~and~~ 1:10 and is not 1:1.

2. The use~~cannabinoid composition~~ according to claim 1, wherein the mass ratio of the cannabidiol to the cannabigerol is from~~between~~ 1:1 to~~and~~ 1:3, or from 1:3 to 1:5, or from 1:5 to 1:7.

3. The use~~cannabinoid composition~~ according to claim 1, wherein the mass ratio of the cannabidiol to the cannabigerol is 1:3.

4. The use~~cannabinoid composition~~ according to any one of claims 1 to 3, wherein the cannabinoid composition further comprises cannabinol.

5. The use~~cannabinoid composition~~ according to claim 4, wherein the mass ratio of the cannabidiol to the cannabinol ranges from 1:0.05 to 1:1.

6. The use~~cannabinoid composition~~ according to claim 4, wherein the mass ratio of the cannabidiol to the cannabinol ranges from 1:0.1 to 1:0.5.

7. The use~~cannabinoid composition~~ according to claim 4, wherein a mass ratio between the cannabidiol, the cannabigerol, and cannabinol is 1:3:0.3.

8. The use~~cannabinoid composition~~ according to any one of claims 1 to 7, wherein the medicament is in a dosage form selected from the group consisting of: ~~for use in the treatment of neurodegenerative diseases.~~ oil agent, granule, tablet, pulvis, capsule, pill, powder, oral liquid, gel, spray, and aerosol.

9. The use~~cannabinoid composition~~ according to any one of claims 1 to 8, wherein the neurodegenerative disease~~s~~ is selected from the group consisting of: ~~include~~ Parkinson's disease, Alzheimer's disease and dementia with Lewy bodies.

~~10. A pharmaceutical composition for use in the treatment of neurodegenerative diseases, wherein the pharmaceutical composition comprising: the cannabinoid~~

~~composition according to any of claims 1 to 7, and a pharmaceutically acceptable carrier.~~

~~11. The pharmaceutical composition according to claim 10, wherein a dosage form of the pharmaceutical composition includes: oil agent, granule, tablet, pulvis, capsule, pill, powder, oral liquid, gel, spray, and aerosol.~~

~~12. A pharmaceutical kit for use in the treatment of neurodegenerative diseases, the pharmaceutical kit comprising: the cannabinoid composition according to any of claims 1 to 7.~~

10. A cannabinoid composition, comprising: cannabidiol and cannabigerol, wherein a mass ratio of the cannabidiol to the cannabigerol is 1:3.

11. The cannabinoid composition according to claim 10, wherein the cannabinoid composition further comprises cannabinol.

12. The cannabinoid composition according to claim 11, wherein the mass ratio of the cannabidiol to the cannabinol ranges from 1:0.05 to 1:1.

13. The cannabinoid composition according to claim 11, wherein the mass ratio of the cannabidiol to the cannabinol ranges from 1:0.1 to 1:0.5.

14. The cannabinoid composition according to claim 11, wherein a mass ratio between the cannabidiol, the cannabigerol, and cannabinol is 1:3:0.3.